CompletedPhase 2NCT05190744

Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

Studying Arginine vasopressin resistance

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Mayo Clinic
Principal Investigator: Fouad Chebib, MD, MD
Mayo Clinic
Intervention: PB(drug)
Enrollment: 36 enrolled
Eligibility: 18 years · All sexes
Timeline: 2022 – 2025

Study locations (1)

Mayo Clinic, Jacksonville, Florida, United States

Collaborators

Otsuka America Pharmaceutical

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05190744 on ClinicalTrials.gov

Other trials for Arginine vasopressin resistance

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE4NCT05044611
AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium
Assistance Publique - Hôpitaux de Paris

See all trials for Arginine vasopressin resistance →

← Back to all trials